Abstract
An 18-year-old boy with X-linked chronic granulomatous disease (CGD) developed Aspergillus fumigatus pneumonia and multifocal osteomyelitis. Treatment with amphotericin B resulted in only moderate improvement of the lesions and was accompanied by considerable toxicity. In contrast, administration of the new triazole drug itraconazole led to complete disappearance of all signs of infection. We conclude that itraconazole may be a valuable new drug for treating invasive aspergillosis in patients with CGD, although the duration of treatment remains to be established.
MeSH terms
-
Adolescent
-
Amphotericin B / therapeutic use*
-
Aspergillosis / complications
-
Aspergillosis / diagnostic imaging
-
Aspergillosis / drug therapy*
-
Aspergillus fumigatus / isolation & purification
-
Chromatography, High Pressure Liquid
-
Granulomatous Disease, Chronic / complications*
-
Granulomatous Disease, Chronic / diagnostic imaging
-
Humans
-
Itraconazole
-
Ketoconazole / analogs & derivatives*
-
Ketoconazole / blood
-
Ketoconazole / therapeutic use
-
Lung Diseases, Fungal / complications
-
Lung Diseases, Fungal / diagnostic imaging
-
Lung Diseases, Fungal / drug therapy*
-
Male
-
Osteomyelitis / drug therapy*
-
Radiography
-
Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use
Substances
-
Itraconazole
-
Amphotericin B
-
Trimethoprim, Sulfamethoxazole Drug Combination
-
Ketoconazole